[go: up one dir, main page]

PE20040898A1 - Nuevos compuestos derivados de pirimidina - Google Patents

Nuevos compuestos derivados de pirimidina

Info

Publication number
PE20040898A1
PE20040898A1 PE2003000839A PE2003000839A PE20040898A1 PE 20040898 A1 PE20040898 A1 PE 20040898A1 PE 2003000839 A PE2003000839 A PE 2003000839A PE 2003000839 A PE2003000839 A PE 2003000839A PE 20040898 A1 PE20040898 A1 PE 20040898A1
Authority
PE
Peru
Prior art keywords
chlorophenylamine
trifluoromethylpyrimidin
cycloalkyl
alkyl
pyrimidine
Prior art date
Application number
PE2003000839A
Other languages
English (en)
Inventor
William Leonard Mitchell
Andrew John Eatherton
Jennifer Margaret Doughty
Derek Anthony Rawlings
Gerard Martin Paul Giblin
Alan Naylor
Brian Peter Slingsby
Andrew Richard Whittington
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31948030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20040898(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0219501A external-priority patent/GB0219501D0/en
Priority claimed from GB0309326A external-priority patent/GB0309326D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20040898A1 publication Critical patent/PE20040898A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE Y ES FENILO OPCIONALMENTE SUSTITUIDO POR 1-3 SUSTITUYENTES; R1 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS; R2 ES (CH2)mR3; m ES 0-1; R3 ES HETEROCICLO NO AROMATICO DE 4-8 ESLABONES OPCIONALMENTE SUSTITUIDO; R4 ES H, ALQUILO C1-6, CICLOALQUILO C3-C6, COCH3, ENTRE OTROS; R6 ES METILO, Cl, CHxFn; n ES 1-3; x ES 0-2; x Y n SUMAN HASTA 3. SON COMPUESTOS PREFERIDOS: CICLOPENTILMETIL-AMIDA DE ACIDO 2-(3-CLOROFENILAMINO)-4-TRIFLUOROMETIL-PIRIMIDIN-5-CARBOXILICO; 1-[2-(2,3-DICLOROFENILAMINO)-4-TRIFLUOROMETILPIRIMIDIN-5-IL]-1-MORFOLIN-4-IL-METANONA Y CICLOPENTILAMIDA DE ACIDO 2-(3-CLOROFENILAMINO)-4-TRIFLUOROMETILPIRIMIDIN-5-CARBOXILICO. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE INVOLUCRA DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES PROVOCADAS DIRECTA O INDIRECTAMENTE POR AUMENTO O DISMINUCION DE LA ACTIVIDAD DEL RECEPTOR DE CANNBINOIDES
PE2003000839A 2002-08-21 2003-08-19 Nuevos compuestos derivados de pirimidina PE20040898A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0219501A GB0219501D0 (en) 2002-08-21 2002-08-21 Compounds
GB0309326A GB0309326D0 (en) 2003-04-24 2003-04-24 Compounds

Publications (1)

Publication Number Publication Date
PE20040898A1 true PE20040898A1 (es) 2005-01-07

Family

ID=31948030

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000839A PE20040898A1 (es) 2002-08-21 2003-08-19 Nuevos compuestos derivados de pirimidina

Country Status (34)

Country Link
US (2) US7635701B2 (es)
EP (2) EP1539712B1 (es)
JP (1) JP4583174B2 (es)
KR (1) KR20050058367A (es)
CN (1) CN100351239C (es)
AP (1) AP2005003219A0 (es)
AR (1) AR041016A1 (es)
AT (2) ATE489369T1 (es)
AU (1) AU2003264076B2 (es)
BR (1) BR0313676A (es)
CA (1) CA2495880C (es)
CY (1) CY1107871T1 (es)
DE (2) DE60317348T2 (es)
DK (1) DK1539712T3 (es)
EA (2) EA012703B1 (es)
EC (1) ECSP055613A (es)
ES (1) ES2295682T3 (es)
IL (2) IL166552A0 (es)
IS (1) IS7749A (es)
MA (1) MA27428A1 (es)
MX (1) MXPA05001960A (es)
MY (1) MY137053A (es)
NO (1) NO20051451L (es)
NZ (1) NZ537886A (es)
OA (1) OA12910A (es)
PE (1) PE20040898A1 (es)
PL (1) PL376047A1 (es)
PT (1) PT1539712E (es)
SI (1) SI1539712T1 (es)
TW (1) TW200410946A (es)
UA (1) UA83194C2 (es)
UY (1) UY27939A1 (es)
WO (1) WO2004018433A1 (es)
ZA (1) ZA200500913B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
WO2004029204A2 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
AR043633A1 (es) * 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
GB0402355D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402356D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
NZ551027A (en) 2004-04-08 2011-01-28 Targegen Inc Benzotriazine inhibitors of kinases
JP5275628B2 (ja) 2004-08-25 2013-08-28 ターゲジェン インコーポレーティッド 複素環式化合物および使用方法
GB0517188D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
EP1966132A2 (en) 2005-12-15 2008-09-10 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2007118041A1 (en) * 2006-04-07 2007-10-18 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
US7935715B2 (en) 2006-07-28 2011-05-03 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
JP5159630B2 (ja) * 2006-09-13 2013-03-06 協和発酵キリン株式会社 縮環複素環誘導体
EA200900403A1 (ru) 2006-09-25 2009-10-30 Бёрингер Ингельхайм Интернациональ Гмбх Соединения, которые модулируют рецептор св2
EP2076499B1 (en) * 2006-10-04 2010-05-12 F.Hoffmann-La Roche Ag Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
WO2008048914A1 (en) * 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
EP2139852A1 (en) 2006-12-19 2010-01-06 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
GB0705803D0 (en) * 2007-03-28 2007-05-02 Glaxo Group Ltd Novel compounds
EP2212694A4 (en) * 2007-11-06 2011-10-12 Univ Emory METHOD OF IDENTIFYING SAFE NMDA RECEPTOR ANTAGONISTS
WO2009061652A1 (en) 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2010005782A1 (en) 2008-07-10 2010-01-14 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the cb2 receptor
KR20110063438A (ko) 2008-09-25 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 선택적으로 조절하는 설포닐 화합물
TW201031649A (en) 2008-12-02 2010-09-01 Organon Nv 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives
TW201031650A (en) * 2008-12-02 2010-09-01 Organon Nv 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione
JPWO2010113834A1 (ja) * 2009-03-30 2012-10-11 アステラス製薬株式会社 ピリミジン化合物
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010147791A1 (en) 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
US8383651B2 (en) 2009-09-22 2013-02-26 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP2013517271A (ja) 2010-01-15 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
WO2011109324A1 (en) 2010-03-05 2011-09-09 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the cb2 receptor
JP5746764B2 (ja) 2010-07-22 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
PT2599774T (pt) * 2010-07-29 2016-09-23 Astellas Pharma Inc Compostos de piridina condensados como ligandos do recetor canabinoide cb2
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
US20150261260A1 (en) * 2013-03-15 2015-09-17 Royce J. Nicholas Method of water-proofing electronic components
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
KR102313314B1 (ko) * 2013-10-23 2021-10-19 아카데미아 시니카 신경퇴행성 질환 및 통증의 예방 및 치료에 사용하기 위한 화합물
US10588974B2 (en) 2016-04-22 2020-03-17 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
US12303487B2 (en) 2018-11-19 2025-05-20 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5518A (en) 1848-04-18 Geaijst-drieb
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5112820A (en) 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
HUT63941A (en) 1992-05-15 1993-11-29 Hoechst Ag Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same
WO1993025190A1 (en) 1992-06-10 1993-12-23 Eastman Kodak Company Surface modified nsaid nanoparticles
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
HUT74464A (en) * 1993-10-12 1996-12-30 Du Pont Merck Pharma 1n-alkyl-n-arylpyrimidinamines and derivatives thereof, and pharmaceutical compositions containing them
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
PL185544B1 (pl) 1995-02-13 2003-05-30 Nowa pochodna podstawionego izoksazolu i środek farmaceutyczny
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
AU726522B2 (en) 1995-09-01 2000-11-09 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
US5811428A (en) * 1995-12-18 1998-09-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
WO1997014407A1 (en) 1995-10-17 1997-04-24 Research Triangle Pharmaceuticals Insoluble drug delivery
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
BR9708574A (pt) 1996-04-12 1999-08-03 Searle & Co Derivados benzeno sulfonamida substituídos como pródrogas de inibidores cox-2
CZ292843B6 (cs) 1996-07-18 2003-12-17 Merck Frosst Canada & Co. Derivát pyridinu a farmaceutický prostředek s jeho obsahem
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ATE281458T1 (de) 1997-09-05 2004-11-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6177103B1 (en) 1998-06-19 2001-01-23 Rtp Pharma, Inc. Processes to generate submicron particles of water-insoluble compounds
WO2000018374A1 (en) 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US7223772B1 (en) 1998-11-03 2007-05-29 Smithkline Beecham Corporation Pyrazolopyridine derivatives as selective cox-2 inhibitors
US6180136B1 (en) 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
CN1213733C (zh) 1998-11-20 2005-08-10 斯凯伊药品加拿大公司 制备稳定的不溶性微粒的悬浮液的方法
US6025683A (en) 1998-12-23 2000-02-15 Stryker Corporation Motor control circuit for regulating a D.C. motor
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
EP1157025B1 (en) 1999-02-27 2004-03-10 Glaxo Group Limited Pyrazolopyridines
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
IL144760A0 (en) 1999-12-08 2002-06-30 Pharmacia Corp Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
CN1275964C (zh) 2000-08-31 2006-09-20 霍夫曼-拉罗奇有限公司 作为细胞增殖抑制剂的7－氧代吡啶并嘧啶
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
EP1363632B1 (en) 2001-01-29 2010-08-25 The University of Connecticut Receptor selective cannabimimetic aminoalkylindoles
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
EP1361879A1 (en) 2001-02-20 2003-11-19 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
FR2839718B1 (fr) 2002-05-17 2004-06-25 Sanofi Synthelabo Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant
CA2487346A1 (en) 2002-06-19 2003-12-31 Schering Corporation Cannabinoid receptor agonists
AU2003244098A1 (en) 2002-06-28 2004-01-19 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
WO2004018434A1 (en) 2002-08-21 2004-03-04 Glaxo Group Limited Pyrimidine compounds
GB0222495D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
GB0222493D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
WO2004029204A2 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides

Also Published As

Publication number Publication date
EP1878725A3 (en) 2008-01-30
IS7749A (is) 2005-03-17
MY137053A (en) 2008-12-31
HK1079193A1 (en) 2006-03-31
DE60317348D1 (de) 2007-12-20
PL376047A1 (en) 2005-12-12
AU2003264076A1 (en) 2004-03-11
EA200500392A1 (ru) 2005-08-25
CN1688552A (zh) 2005-10-26
US20100041654A1 (en) 2010-02-18
CA2495880C (en) 2010-04-27
NO20051451D0 (no) 2005-03-18
AR041016A1 (es) 2005-04-27
MXPA05001960A (es) 2005-04-28
BR0313676A (pt) 2005-06-21
EP1878725A2 (en) 2008-01-16
ECSP055613A (es) 2005-04-18
EA200700934A1 (ru) 2007-08-31
CA2495880A1 (en) 2004-03-04
IL185549A0 (en) 2008-01-06
JP4583174B2 (ja) 2010-11-17
ATE489369T1 (de) 2010-12-15
EA012703B1 (ru) 2009-12-30
EP1539712B1 (en) 2007-11-07
ATE377591T1 (de) 2007-11-15
US7635701B2 (en) 2009-12-22
EP1539712A1 (en) 2005-06-15
DE60317348T2 (de) 2008-08-28
DK1539712T3 (da) 2008-03-17
EA010130B1 (ru) 2008-06-30
TW200410946A (en) 2004-07-01
DE60335151D1 (de) 2011-01-05
UA83194C2 (ru) 2008-06-25
NZ537886A (en) 2007-05-31
OA12910A (en) 2006-10-13
US20060293354A1 (en) 2006-12-28
WO2004018433A1 (en) 2004-03-04
AU2003264076B2 (en) 2007-09-20
AP2005003219A0 (en) 2005-03-31
EP1878725B1 (en) 2010-11-24
CN100351239C (zh) 2007-11-28
KR20050058367A (ko) 2005-06-16
UY27939A1 (es) 2004-03-31
ZA200500913B (en) 2006-07-26
MA27428A1 (fr) 2005-07-01
NO20051451L (no) 2005-03-18
IL166552A0 (en) 2006-01-15
JP2006501228A (ja) 2006-01-12
CY1107871T1 (el) 2013-06-19
PT1539712E (pt) 2008-02-08
ES2295682T3 (es) 2008-04-16
SI1539712T1 (sl) 2008-04-30

Similar Documents

Publication Publication Date Title
PE20040898A1 (es) Nuevos compuestos derivados de pirimidina
RU2436776C2 (ru) ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20071009A1 (es) Compuestos derivados de fenoxipiperidinas como antagonistas de histamina h3
PE20120355A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20080318A1 (es) Derivados de diceto-piperazina y piperidina como agentes antivirales
AR036114A1 (es) Tetrahidroimidazol[1,2-a]pirazinas y tetrahidrotriazol[4,3-a]pirazinas como inhibidores de la dipeptidil peptidasa utiles para el tratamiento o la prevencion de la diabetes
CY1107008T1 (el) Παραγωγο βενζιμιδαζολης και χρηση ως ανταγωνιστου υποδοχεα aii
PE20081530A1 (es) Nuevos compuestos 617
PE20050864A1 (es) Compuestos de heterociclilamino como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
AR017021A1 (es) Acido 2-hidroxiacetico
PE20030226A1 (es) Compuestos arilicos sustituidos con quinuclidinas para el tratamiento de enfermedades
PE20120101A1 (es) Pirazoles fungicidas
PE20060241A1 (es) 2-quinolil-oxazoles sustituidos como inhibidores de pde4
PE20070078A1 (es) Compuestos heterociclicos macrociclicos como inhibidores de aspartil proteasa
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
PE20040666A1 (es) Derivados novedosos de piperidina
ATE238661T1 (de) Fungizide zusammensetzung enthaltend ein 1,2,3- thiadiazolderivat sowie deren verwendung
PE20040864A1 (es) Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
PE20120657A1 (es) Compuesto para el tratamiento de trastornos metabolicos
PE20000061A1 (es) Derivados de tiazol
PE20060589A1 (es) FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
PE20030930A1 (es) Derivados de tiazol como antagonistas del receptor npy

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed